The first participant has already received a dose. Earlier this week, competitor Pfizer began a similar study of its own reformulated shots:
Moderna has begun testing an omicron-specific COVID-19 booster in healthy adults.
The company announced Wednesday that the first participant had received a dose. Earlier this week, competitor PfizerIt’s not clear whether global health authorities will order a change to the vaccine recipe in the wake of the hugely contagious omicron variant. The original vaccines still offer good protection against death and severe illness.and elsewhere show a booster dose strengthens that protection and improves the chances of avoiding even a milder infection.
Moderna pointed to a small study published in the New England Journal of Medicine on Wednesday that showed antibodies able to target omicron persisted for six months after a booster dose, although the levels were dropping. Moderna’s new study will enroll about 600 people who already have received either two doses of the company’s original shots or two plus a booster dose. All the volunteers will receive a dose of the experimental omicron-matched version.The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.